Omnio

Experts in plasminogen research

We develop disruptive treatments that improve lives while lowering the overall cost of health care with plasminogen-based therapeutics. Unlike other products available on the market, plasminogen has been shown to be a key regulatory molecule that activates all stages of the wound healing process.

More about us

Team

Omnio is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations.

Drug Development

Omnio is developing recombinant plasminogen for treatment of chronic wounds.

Wound healing

The management of chronic wounds is an enormous clinical and economic burden on the health care system.

Clinical development plan

We focus on delivering transformative treatment for chronic wounds and where there is little to no pharmacologically active treatment available today.

TRANSFORMING WOUNDHEALING

Chronic wounds impose substantial costs on the healthcare system. The global $12.8 bn advanced wound care market is driven by an ageing population and rising incidence of ailments such as diabetes. Our novel treatment will increase quality of life for patients, give access to an effective wound healing treatment for clinicians and reduce the economic burden on the health care system.